Kedbumin Market Report 2026

Kedbumin Market Overview

• The Kedbumin market growth in the historic period has been driven by high incidence of hypoalbuminemia, long standing clinical use of albumin • Market expansion is supported by rising intensive care admissions, growth in liver disease prevalence • Growth Driver: Rising Prevalence Of Chronic Diseases Driving The Growth Of The Kedbumin Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Kedbumin Market?

Kedbumin refers to a therapeutic product designed to manage and treat conditions related to protein deficiency, typically used in medical settings to support patients with hypoalbuminemia or other related disorders. Kedbumin is a clear, slightly viscous solution with an amber, yellow, or green hue. It is stabilized with the inclusion of 0.08 mmol sodium caprylate and 0.08 mmol sodium acetyltryptophan per gram of albumin. The main indication types of kedbumin are treatment of hypoalbuminemia, fluid resuscitation, management of liver diseases, treatment of burns and trauma, and others. Hypoalbuminemia is a condition where albumin levels in the blood are low, leading to potential health complications. The various formulations are injectable formulations and lyophilized powders for reconstitution, and patient demographics include pediatric patients, adult patients, and geriatric patients. The various distribution channels are direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, and it is used by various end users such as hospitals, specialty clinics, home healthcare providers, pharmaceutical and biotechnology companies, and research institutions.

What Is The Kedbumin Market Growth Forecast?

The growth in the forecast period can be attributed to rising intensive care admissions, growth in liver disease prevalence, expansion of surgical procedures, increasing plasma collection capacity, improved critical care infrastructure. Major trends in the forecast period include continued demand for albumin therapies, growth in critical care volume expansion, rising use in liver and trauma management, expansion of plasma derived therapeutics, strengthening hospital infusion practices.

Global Kedbumin Market Segmentation

1) By Indication: Treatment Of Hypoalbuminemia, Fluid Resuscitation, Management Of Liver Diseases, Treatment Of Burns And Trauma, Other Indications 2) By Formulation: Injectable Formulation, Lyophilized Powder For Reconstitution 3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients 4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies 5) By End User: Hospitals, Specialty Clinics, Home Healthcare Providers, Pharmaceutical And Biotechnology Companies, Research Institutions

What Are The Drivers Of The Kedbumin Market?

The rising prevalence of chronic diseases is expected to propel the growth of the kedbumin market going forward. A chronic disease is a form of illness that lasts three months or more and can deteriorate with time. The rising prevalence of chronic diseases is largely driven by increasingly sedentary lifestyles, with reduced physical activity contributing to higher rates of conditions such as diabetes and cardiovascular disease. Kedbumn helps in managing complications like ascites and spontaneous bacterial peritonitis by improving circulatory function and reducing fluid accumulation. For instance, in June 2023, according to the report published by Kidney Research UK, a UK-based non-profit organization, currently, approximately 7.2 million people in the UK are living with chronic kidney disease, representing over 10% of the population. Of these, 3.25 million are in the advanced stages of the disease, while an additional 3.9 million are in the early stages. By 2033, the number of individuals affected by chronic kidney disease is projected to rise to 7.61 million. Therefore, the rising prevalence of chronic diseases is driving the growth of the kedbumin industry. The growing aging population is expected to drive the kedbumin market going forward. The aging population consists of individuals aged 65 and older, a trend driven by increased life expectancy and declining birth rates. This demographic shift is fueled by advancements in healthcare, medical technology, and enhanced living conditions. Kedbumin, a plasma-derived albumin solution, supports the aging population by managing conditions such as hypovolemia, hypoalbuminemia, and related complications, improving overall health and recovery outcomes. For instance, in January 2024, according to the statistics published by the Population Reference Bureau (PRB), a US-based nonprofit organization, it is anticipated that the number of Americans 65 and older will climb from 58 million in 2022 to 82 million in 2050 (a 47% increase) and that their proportion of the overall population will increase from 17% to 23%. Therefore, the growing aging population drives the kedbumin industry.

Key Players In The Global Kedbumin Market

Major companies operating in the kedbumin market are Kedrion SpA

What Are Latest Mergers And Acquisitions In The Kedbumin Market?

In July 2023, Kedrion Biopharma Inc., a leading Italy-based producer of human blood plasma-derived therapies, completed the merger of Prometic BioTherapeutics Inc. to reinforce its U.S. commercial structure and strengthen its position in the plasma-derived therapeutics market. This integration improves operational efficiency and supports key products such as Kedbumin by unifying manufacturing and distribution capabilities. Prometic BioTherapeutics Inc. is a US-based plasma operations company, contributed complementary expertise and infrastructure to the merged organization.

Regional Insights

North America was the largest region in the kedbumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Kedbumin Market?

The kedbumin market consists of sales of kedbumin products for medical and therapeutic use. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Kedbumin Market Report 2026?

The kedbumin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the kedbumin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.